Thriving Growth Prospects: Single-Use Bioreactors Market Forecasted to Achieve USD 10.0 Billion by 2028, Powered by 19.0% CAGR

single-use bioreactors market was a rapidly growing segment within the biotechnology and pharmaceutical industries. Single-use bioreactors, also known as disposable bioreactors, are a type of bioreactor that is designed for single-use applications, offering various advantages over traditional stainless-steel bioreactors.

Request for Sample PDF @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=49113750&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Single-Use Bioreactors Market in terms of revenue was estimated to be worth $4.2 billion in 2023 and is poised to reach $10.0 billion by 2028, growing at a CAGR of 19.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as the increasing adoption of single-use bioreactors among startups and SMEs, lower operational complexity of single-use bioreactors compared to conventional stainless-steel bioreactors, reduced energy and water consumption, growing size of the biologics and biosimilars market, and technological advancements in single-use bioreactors.

Key factors driving the growth of the single-use bioreactors market include:

Cost-effectiveness: Single-use bioreactors eliminate the need for extensive cleaning and validation processes, reducing operational costs and saving time in-between batches.

Flexibility and scalability: These bioreactors are available in various sizes and configurations, making them suitable for a wide range of applications and allowing for easy scale-up or scale-down based on production needs.

Reduced cross-contamination risk: Since single-use bioreactors are disposable, the risk of cross-contamination between batches is minimized, which is particularly crucial in the production of biologics and vaccines.

Faster setup and turnaround times: The simplicity of setup and reduced cleaning requirements lead to faster turnaround times between batches, enhancing production efficiency.

Increasing demand for biologics and personalized medicine: The rise in demand for biopharmaceuticals, such as monoclonal antibodies and cell therapies, has driven the adoption of single-use bioreactors in biopharmaceutical manufacturing.

Support from regulatory bodies: Regulatory authorities, like the FDA, have recognized the benefits of single-use bioreactors in certain applications, leading to increased acceptance and adoption within the industry.

Browse Complete Report @ https://www.marketsandmarkets.com/Market-Reports/single-use-bioreactor-market-49113750.html?utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

The Asia Pacific region is the fastest-growing region of the single-use bioreactors market.

The Asia Pacific market is expected to register the highest CAGR during the forecast period. Factors such as the growing biopharmaceutical industry, rising investments by pharmaceutical & biotechnology companies, and the growing number of CROs & CMOs in several Asia Pacific countries are supporting the growth of the market in the region.

Key Market Players:

Key players in the single-use bioreactors Market are Sartorius AG (Germany), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck Millipore (Germany).

Recent Developments:

• Sartorius GA (Germany) planned to invest in growing its operations by establishing new R&D laboratories and digitalizing & automating equipment, among other approaches. This development was aimed at meeting the high demand from the biopharmaceutical industry.

• Danaher Corporation (US) subsidiary, Cytiva invested around USD 8 million to expand its Fast Trak center in Shanghai, China. The Single-use Technologies (SUT) center of excellence in Asia offers new product R&D tests and validation with an aim to facilitate the industry's application of SUT throughout the region.

• Thermo Fisher Scientific (US) opened its largest single-use technology manufacturing site in Greater Nashville with an investment of USD 105 million to meet the growing demand for the bioprocessing materials needed to produce vaccines and breakthrough therapies for cancer and other diseases.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=49113750&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/proteomic-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/proteomics.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.